Tag «approvals 2024»

Vanzacaftor

Vanzacaftor FDA APPROVED vanzacaftor, tezacaftor, and deutivacaftor, 12/20/2024, Alyftrek , To treat cystic fibrosis (14S)-8-[3-(2-dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2λ6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one 13H-17,20-Methano-8,12-nitrilo-12H-pyrido[3,2-d][1,2,6,13]thiatriazacyclooctadecin-5(6H)-one, 2-[3-(2-dispiro[2.0.2.1]hept-7-ylethoxy)-1H-pyrazol-1-yl]-14,15,16,17,18,19-hexahydro-19,19-dimethyl-, 7,7-dioxide, (17S)- (14S)-8-[3-(2-Dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2?6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one (14S)-8-[3-(2-dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2|E6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is …

Probenecid

Probenecid 4-(dipropylsulfamoyl)benzoic acid C13H19NO4S, 285.359 FDA APPROVED, 10/25/2024, sulopenem etzadroxil, probenecid, Orlynvah, To treat uncomplicated urinary tract infections (uUTI)Drug Trial Snapshot Probenecid, also sold under the brand name Probalan, is a medication that increases uric acid excretion in the urine. It is primarily used in treating gout and hyperuricemia. Probenecid was developed as an alternative to caronamide[1] to competitively inhibit renal excretion of …

Sulopenem

Sulopenem (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid FDA APPROVED sulopenem etzadroxil, probenecid, 10/25/2024, To treat uncomplicated urinary tract infections (uUTI)Drug Trial Snapshot Sulopenem (CP-70,429) is a thiopenem antibiotic derivative from the penem family, which unlike most related drugs is orally active. It was developed in Japan in the 1990s, and has been approved to treat uncomplicated urinary tract infections in combination with probenecid (Brand …

Revumenib

Revumenib FDA APPROVED 11/15/2024, Revuforj, To treat relapsed or refractory acute leukemia N-ethyl-2-[4-[7-[[4-(ethylsulfonylamino)cyclohexyl]methyl]-2,7-diazaspiro[3.5]nonan-2-yl]pyrimidin-5-yl]oxy-5-fluoro-N-propan-2-ylbenzamide Ingredient UNII CAS InChI Key Revumenib citrate YL4RYN734D 2761046-45-9 UBXFWTFPYATLBT-SGBGZXBGSA-N Revumenib sesquifumarate 75HI05N8HS 2169919-22-4 AXNUWYROYVRYIM-OQIJCFCCSA-N Revumenib, sold under the brand name Revuforj, is an anti-cancer medication used for the treatment of acute leukemias harboring lysine methyltransferase 2A gene (KMT2A) rearrangements.[1] It is designed to disrupt the interaction between menin and KMT2A (also known as MLL), …

Acoramidis

Acoramidis 292.30 g/mol, C15H17FN2O3 3-[3-(3,5-dimethyl-1H-pyrazol-4-yl)propoxy]-4-fluorobenzoic acid FDA APPROVED 11/22/2024, Attruby To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosisDrug Trials Snapshot Ingredient UNII CAS InChI Key Acoramidis hydrochloride VY9C88C2NV 2242751-53-5 MGFZEARHINUOMX-UHFFFAOYSA-N Acoramidis, sold under the brand name Attruby, is a medication used for the treatment of cardiomyopathy.[1] It is a near-complete (>90%) transthyretin stabilizer, developed to mimic the protective properties of the naturally-occurring …

Landiolol

Landiolol FDA APPROVED 11/22/2024, Rapiblyk, To treat supraventricular tachycardia C25H39N3O8509.6 g/mol [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate Landiolol, sold under the brand name Onoact among others, is a medication used for the treatment of tachycardia, atrial fibrillation, and atrial flutter.[1][4] It is a beta-adrenergic blocker;[4] an ultra short-acting, β1-superselective intravenous adrenergic antagonist, which decreases the heart rate effectively with less negative effect on blood pressure or myocardial contractility.[6][7] In comparison …

Iomeprol

Iomeprol WeightAverage: 777.089Monoisotopic: 776.8541 Chemical FormulaC17H22I3N3O8 FDA APPROVED, 11/27/2024, Iomervu, For use as a radiographic contrast agent 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-methylamino]-2,4,6-triiodobenzene-1,3-dicarboxamide Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging.[1][2][3] Iomeprol was approved for medical use in the United States in November 2024.[1][4][5] Experimental Properties Property Value Source melting point (°C) 285-291 https://www.chemos.de/import/data/msds/GB_en/78649-41-9-A0017152-GB-en.pdf boiling …

Crinecerfont

Crinecerfont CAS 752253-39-7 SSR125543 SSR 125543 SSR-125543, WHO 10958, UNII-MFT24BX55I, 06-RORI,NBI-74788 FDA APPROVED 12/13/2024, Crenessity, To treat classic congenital adrenal hyperplasia Press Release 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine WeightAverage: 483.04Monoisotopic: 482.1594906 Chemical FormulaC27H28ClFN2OS CAS No. : 321839-75-2 Molecular Weight 519.50 Formula C27H29Cl2FN2OS Crinecerfont, sold under the brand name Crenessity, is a medication used for the treatment of congenital adrenal hyperplasia.[1] It is a corticotropin-releasing factor type 1 …

Ensartinib

Ensartinib X396, X 396 6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-[(3R,5S)-3,5-dimethylpiperazine-1-carbonyl]phenyl]pyridazine-3-carboxamide FDA 12/18/2024, Ensacove, To treat non-small cell lung cancer Ensartinib, sold under the brand name Ensacove, is an anti-cancer medication used for the treatment of non-small cell lung cancer.[1] Ensartinib is an Anaplastic lymphoma kinase (ALK) inhibitor used as the salt ensartinib hydrochloride.[1] It is taken by mouth.[1] The most common adverse reactions include rash, musculoskeletal pain, constipation, cough, …

BENZGALANTAMINE

BENZGALANTAMINE CAS 224169-27-1 Benzgalantamine gluconate, 1542321-58-3 6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, benzoate (ester), (4as,6r,8as)- Formula C24H25NO4 Molar mass 391.467 g·mol−1 External IDs GLN-1062 gluconate UNIILN7PMJ4P57 CAS Number1542321-58-3 WeightAverage: 587.622Monoisotopic: 587.236661015 Chemical FormulaC30H37NO11 Benzgalantamine, sold under the brand name Zunveyl, is a medication used for the treatment of mild to moderate dementia of the Alzheimer’s type.[1] It is a cholinesterase inhibitor.[1] Benzgalantamine is a prodrug of galantamine.[1] The most common …